Other substances

Abacavir

nucleoside analog reverse-transcriptase inhibitor

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

2
 Supporting references
0
 Contradictory references
8
 AI-suggested references
0
 Clinical trials

General information

Abacavir is a nucleoside reverse transcriptase inhibitor analog of guanosine, which is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. Abacavir was approved for the use in USA in 1998. It is used in combination with other agents in the therapy of the human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS). It decreases HIV viral loads, retartds or prevents the damage to the immune system, and reduces the risk of developing AIDS.

Regarding SARS-CoV-2, our AIM tool found the data that abacavir could help against SARS-CoV-2 by inhibiting its replication. 

Abacavir on PubChem
Abacavir on DrugBank
Abacavir on Wikipedia

Synonyms

abacavir sulfate

Marketed as

ZIAGEN®

 

Structure image - Abacavir

C14H18N6O

Supporting references

Link Tested on Impact factor Notes Publication date
Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model
Preprint In silico 		in silico Feb/02/2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
in silico Feb/22/2020

AI-suggested references

Link Publication date
Network bioinformatics analysis provides insight into drug repurposing for COVID-19.
Mar/30/2021
Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19
Aug/05/2020
A computational approach for the screening of potential antiviral compounds against SARS-CoV-2 protease: Ionic liquid vs herbal and natural compounds.
Jan/07/2021
A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19
Jun/18/2020
The screening and evaluation of potential clinically significant HIV drug combinations against the SARS-CoV-2 virus.
Jan/30/2021
Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection.
Mar/15/2021
Identification of potential natural inhibitors of the receptor-binding domain of the SARS-CoV-2 spike protein using a computational docking approach
Aug/21/2020
A Study of 3CLpros as Promising Targets against SARS-CoV and SARS-CoV-2.
Apr/03/2021
Export (.csv)